- A new U.S. government platform will refer consumers directly to drug manufacturers starting in early 2026.
- Pfizer is the first major pharmaceutical company to join the site, agreeing to match prescription drug prices with those in other developed nations.
- Pfizer’s participation triggered a 6.8% jump in its share price, though the stock remains below last year’s levels.
- The agreement removes pharmacy benefit managers from the supply chain and implements “Most Favored Nation” pricing to align U.S. costs with global rates.
- Pfizer committed $70 billion to U.S. research and development, while the administration granted a three-year tariff grace period.
The U.S. government announced a new drug purchasing website designed to change how Americans buy prescription medicines, with Pfizer joining as the first major pharmaceutical partner. The government will launch the platform in early 2026, offering a direct-to-consumer model that bypasses traditional pharmacy benefit managers and links prices for U.S. medications to those in other developed countries.
Shares of Pfizer rose 6.8% after Tuesday’s announcement, although they remain 13.3% lower than this time last year. The company plans to cut average prices of primary care treatments by 50% and will reduce some drugs by up to 85%. The site will direct consumers to buy medications through manufacturer channels rather than selling medicines directly, according to senior administration officials.
Albert Bourla, CEO of Pfizer, said, “We now have the certainty and stability we need on two critical fronts, tariffs and pricing, that have suppressed the industry’s valuations to historic lows.” Pfizer will invest $70 billion in U.S. research and development over the next few years. In return, the government will delay planned tariffs on pharmaceutical imports for three years.
Other drugmakers saw similar gains, with Merck up 6.8%, Eli Lilly gaining 5%, and Johnson & Johnson increasing 2%. Officials reported that more companies have either joined or started negotiations to participate in the new system.
The agreement uses a “Most Favored Nation” pricing model, which sets U.S. medication prices in line with the lowest costs from countries such as Canada, the United Kingdom, Germany, and Japan. Pfizer will provide these matched prices for Medicaid and other key markets beginning in 2026.
Bourla stated, “We’ve established a balanced global pricing approach that continues to recognize the value of innovation while ensuring prices in the U.S. and other developed countries are both reasonable and sustainable.” The administration described this move as an end to “global price gouging at the expense of American families.”
Senior officials said some companies are still discussing pricing, and investor response suggests clarity on regulations is viewed positively, though some analysts question the immediate benefit for insured patients. For more background on Albert Bourla, visit his Wikipedia page.
✅ Follow BITNEWSBOT on Telegram, Facebook, LinkedIn, X.com, and Google News for instant updates.
Previous Articles:
- Eli Lilly, Pfizer Surge as Trump Unveils Drug Price-Cut Plan
- MEXC Ventures Boosts Ethena Investment to $66M as USDe Soars
- US Shutdown Threat Freezes Crypto Bill as Bitcoin Rally Stalls
- SEC’s Hester Peirce Champions Crypto Innovation at Black Summit
- Ripple CTO David Schwartz Steps Down, Joins Board for New Role
